Cirrhotic Cardiomyopathy Predicts Post‐Transplant Cardiovascular Disease: Revelations of The New Diagnostic Criteria

2021 ◽  
Author(s):  
Manhal Izzy ◽  
Anna Soldatova ◽  
Xin Sun ◽  
Mounika Angirekula ◽  
Kristin Mara ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Diagnostic Criteria ◽  
Cirrhotic Cardiomyopathy ◽  
Post Transplant

Post-transplant Cardiovascular Disease

2010 ◽  
pp. 237-254
Author(s):  
Phuong-Anh T. Pham ◽  
Carmen Slavov ◽  
Phuong-Thu T. Pham ◽  
Alan H. Wilkinson
Keyword(s):  
Cardiovascular Disease ◽  
Post Transplant

scholarly journals Migraine and cardiovascular disease

2011 ◽  
Vol 69 (1) ◽  
pp. 122-129 ◽  
Author(s):  
Marcelo E. Bigal
Keyword(s):  
Myocardial Infarction ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Diagnostic Criteria ◽  
Epidemiological Study ◽  
Cardiovascular Mortality ◽  
Coronary Revascularization ◽  
Meta Analysis ◽  
Established Risk Factor ◽  
The Brain

Migraine, especially migraine with aura is an established risk factor for ischemic lesions of the brain. Recent evidence has also linked migraine with and without aura to a broader range of ischemic vascular disorders including angina, myocardial infarction, coronary revascularization, claudication and cardiovascular mortality. The topic is therefore of considerable interest. Accordingly, herein we review the association between migraine and cardiovascular disease. We start by briefly presenting diagnostic criteria for migraine and revising its pathophysiology. We follow by summarizing the evidence on the topic. We then briefly present the results of a recent meta-analysis. We close by highlighting results of a large epidemiological study conducted after the publication of the meta-analysis.

scholarly journals Elevated Post-transplant Levels of Neopterin are Associated with Poorer long-term Graft Outcome

Pteridines ◽  
2004 ◽  
Vol 15 (3) ◽  
pp. 113-119 ◽  
Author(s):  
S. O. Grebe ◽  
U. Kuhlmann ◽  
T. F. Müller
Keyword(s):  
Cardiovascular Disease ◽  
Graft Survival ◽  
Chronic Allograft Nephropathy ◽  
Wilcoxon Test ◽  
Rank Test ◽  
Post Transplant ◽  
Graft Outcome ◽  
Log Rank Test ◽  
Inflammatory Burden

Abstract Chronic allograft nephropathy (CAN) and death with functioning graft due to cardiovascular disease (CVD) are the key determinants for long-term renal allograft survival. Chronic allograft nephropathy and cardiovascular disease are seen as manifestations of a single disease entity with a common pathogenesis including inflammation and accelerated atherogenesis. Therefore we investigated the relation between early post-transplant inflammatory burden and long-term graft survival. In 64 consecutive renal transplant patients the acute phase reactants serum amyloid A (SAA) and serum C-reactive protein (S-CRP) as well as the macrophage product neopterin in urine (U-NEOP) and serum (S-NEOP) were determined daily during the immediate postoperative period (mean p.o.obs. χ = 29.2 ± 8.7 days, total of Σ = 1869 days). SAA and CRP were measured with high-sensitive assays (in mg/1; immune nephelometry, Dade Behring Co., Marburg, Germany), NEOP was measured with ELISA-technique (Brahms, Berlin, Germany) and related to serum and urine creatinine levels, resp. (in μπιοΐ/mol creatinine). The association between the mean values of these parameters and the survival distribution function of the 64 patients was tested using the log rank test and the Wilcoxon-test. In this analysis graft loss was defined as either resumption of dialysis treatment or patient death with functioning graft. The 1- and 5- year graft survival rates in our patients were 93% and 76%, resp. The markers showed the following mean post-transplant levels: S-CRP χ = 21.3 ± 16.1 mg/1, SAA χ = 10.1 ± 6.5 mg/1, U-NEOP χ = 602 ± 427 mmol/mol creatinine and S-NEOP χ = 81 ± 60 μπιοΐ/mol creatinine. Both log rank test and Wilcoxon-test provided evidence that the graft survival is negatively related to the post-transplant levels of U-NEOP (p = 0.009 and ρ = 0.027, resp.). The markers S-NEOP (p = 0.074 and ρ = 0.116, resp.), SAA (p = 0.599 and ρ = 0.294, resp.), and S-CRP (p = 0.059 and ρ = 0.358, resp.) did not reach statistical significance. These findings support the impact of the inflammatory burden on graft survival. In particular, elevated post-transplant neopterin values, reflecting activated innate and adaptive responses, are predictive for long-term graft outcome.

Factors associated with the presence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria

2020 ◽  
Vol 73 ◽  
pp. S739-S740
Author(s):  
Marcel Razpotnik ◽  
Simona Bota ◽  
Philipp Wimmer ◽  
Michael Hackl ◽  
Gerald Lesnik ◽  
...  
Keyword(s):  
Diagnostic Criteria ◽  
Cirrhotic Cardiomyopathy ◽  
Factors Associated

Prevention of Post-transplant Cardiovascular Disease - Report and Recommendations of an Ad Hoc Group1

2002 ◽  
Vol 2 (6) ◽  
pp. 491-500 ◽  
Author(s):  
Andrew D. Bostom ◽  
Robert S. Brown ◽  
Blanche M. Chavers ◽  
Thomas M. Coffman ◽  
Fernando G. Cosio ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Ad Hoc ◽  
Post Transplant

scholarly journals Post-Transplant Cardiovascular Disease

2021 ◽  
pp. CJN.00520121
Author(s):  
Kelly A. Birdwell ◽  
Meyeon Park
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Kidney Transplant ◽  
Optimal Strategies ◽  
Future Research ◽  
Kidney Transplant Recipients ◽  
Post Transplant ◽  
Treatment And Prevention ◽  
Artery Disease

Cardiovascular disease remains a leading cause of death and morbidity in kidney transplant recipients and a common reason for post-transplant hospitalization. Several traditional and nontraditional cardiovascular risk factors exist, and many of them present pretransplant and worsened, in part, due to the addition of immunosuppression post-transplant. We discuss optimal strategies for identification and treatment of these risk factors, including the emerging role of sodium-glucose cotransporter 2 inhibitors in post-transplant diabetes and cardiovascular disease. We present common types of cardiovascular disease observed after kidney transplant, including coronary artery disease, heart failure, pulmonary hypertension, arrhythmia, and valvular disease. We also discuss screening, treatment, and prevention of post-transplant cardiac disease. We highlight areas of future research, including the need for goals and best medications for risk factors, the role of biomarkers, and the role of screening and intervention.

Sign in / Sign up

Export Citation Format

Share Document